Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
The patient took four doses of Vivotif vaccine every day instead of every other day; Case reference number US-BN-2025-000127 is a spontaneous case initially received from consumer via Communication (reference number: USBAV25-0121) on 15-Jan-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 12-Jan-2025, the patient took first dose of Vivotif vaccine (batch number: unknown), at an unknown dose, orally, for indication reported as travel. On 13-Jan-2025, one day after the first dose, the patient took second dose of Vivotif vaccine (batch number: unknown), at an unknown dose, orally (explicitly coded as 'Inappropriate schedule of vaccine administered'). On 14-Jan-2025, two days after the first dose, the patient took dose of Vivotif vaccine (batch number: unknown), at an unknown dose, orally (explicitly coded as 'Inappropriate schedule of vaccine administered'). On 15-Jan-2025, three days after the first dose, reported as today, the patient took fourth and last dose of Vivotif vaccine (batch number: unknown), at an unknown dose, orally (explicitly coded as 'Inappropriate schedule of vaccine administered'). At the time of initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A female patient of unspecified age took second dose of Vivotif vaccine, one day after the first dose, at an unknown dose, orally which is considered as inappropriate schedule of vaccine administered. Two days and three days after the first dose, the patient received dose of Vivotif vaccine, at an unknown dose, orally which is also considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A female patient of unspecified age took second dose of Vivotif vaccine, one day after the first dose, at an unknown dose, orally which is considered as inappropriate schedule of vaccine administered. Two days and three days after the first dose, the patient received dose of Vivotif vaccine, at an unknown dose, orally which is also considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None